GHB: Effects, Withdrawal and Treatment

GHB：影响、戒断和治疗

• 批准号: 6795308
• 负责人: KAREN A MIOTTO
• 金额: $ 16.77万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6795308
• 关键词: clinical research; clinical trial phase I; detoxification; drug abuse chemotherapy; drug addiction; drug screening /evaluation; drug withdrawal; electroencephalography; gamma hydroxybutyrate; human middle age (35-64); human subject; human therapy evaluation; longitudinal human study; lorazepam; neuropsychological tests; patient oriented research; pentobarbital; young adult human (21-34)

DESCRIPTION (provided by applicant): Career Goals: The candidate is a psychiatrist whose goal is to expand her research and academic activities in the field of addiction medicine. Her immediate career goal is to obtain the training and experience necessary for becoming an independent investigator. Her professional goal is to become an academic resource in the field of addiction with a focus on evaluation of medications. Research Career Development Plan: The candidate proposes to obtain a Master of Science (M.S.) in Clinical Research Design and Statistical Analysis (CRDSA) from the University of Michigan School of Public Health. This program is designed specifically for physicians and other health care professionals involved in clinical research. In addition to this coursework, the applicant's career development plan draws on the resources of a large, well established addiction research group, the Integrated Substance Abuse Program (ISAP) at UCLA, and includes a program of supervision by experts in their respective fields in the qualitative and quantitative aspects of study design and methodology. Description of the research projects: The proposed research plan is designed to objectively describe signs and symptoms of GHB withdrawal, identify predictors of withdrawal severity and treatment response, and develop and validate treatment guidelines for GHB withdrawal. There has been a sharp rise in the number of GHB related emergency room visits in the United States over the past few years, yet little is known about effective treatment of GHB withdrawal and dependence. The signs and symptoms of GHB withdrawal begin one to six hours after last use, and may escalate rapidly and unpredictably to delirium, agitation, and psychosis. Given the rapid, progressive and serious nature of GHB withdrawal symptoms, there is a crucial need to develop improved treatments. There has been little systematic study of the signs and symptoms of withdrawal, and controlled studies on the effectiveness of treatment of these symptoms are lacking.

描述（由申请人提供）： 职业目标：候选人是一名精神病学家，其目标是扩大成瘾医学领域的研究和学术活动。她的近期职业目标是获得成为一名独立调查员所需的培训和经验。她的职业目标是成为成瘾领域的学术资源，重点是药物评估。 研究职业发展计划：候选人建议获得密歇根大学公共卫生学院临床研究设计和统计分析（CRDSA）理学硕士学位（M.S.）。该计划专为参与临床研究的医生和其他医疗保健专业人员而设计。除了本课程之外，申请人的职业发展计划还利用了加州大学洛杉矶分校的综合药物滥用计划（ISAP）这一大型、完善的成瘾研究小组的资源，并包括由各领域专家进行的监督计划研究设计和方法的定性和定量方面。 研究项目描述：拟议的研究计划旨在客观描述 GHB 戒断症状和体征，确定戒断严重程度和治疗反应的预测因素，并制定和验证 GHB 戒断治疗指南。过去几年，美国因 GHB 相关急诊就诊的人数急剧增加，但对于 GHB 戒断和依赖的有效治疗却知之甚少。 GHB 戒断症状和体征在最后一次使用后一到六个小时开始出现，并可能迅速且不可预测地升级为谵妄、烦躁和精神病。鉴于 GHB 戒断症状的快速、进行性和严重性，迫切需要开发改进的治疗方法。对戒断症状和体征的系统研究很少，也缺乏对这些症状治疗有效性的对照研究。